Literature DB >> 17621632

Regulation of c-Met signaling by the tetraspanin KAI-1/CD82 affects cancer cell migration.

Miho Takahashi1, Tsuyoshi Sugiura1, Masakazu Abe1, Koutaro Ishii1, Kanemitsu Shirasuna1.   

Abstract

It has been proposed that the metastasis suppressor CD82/KAI-1, which is a member of the tetraspanin superfamily, regulates biological activity by associating with cell surface receptors or proteins. We show a novel association between CD82 and the hepatocyte growth factor (HGF) receptor c-Met. Although ectopic expression of CD82 in nonsmall cell lung carcinoma cells did not affect the tyrosine phosphorylation of c-Met, these cells showed significant suppression of HGF-induced lamellipodial protrusion and cell migration. CD82 selectively attenuated c-Met signaling via the Ras-Cdc42/Rac and the phosphatidylinositol 3-kinase/Cdc42/Rac pathways. In contrast, another c-Met signaling pathway that involves phosphatidylinositol 3-kinase/Akt and phosphatidylinositol 3-kinase/mitogen activated protein kinase was not affected by CD82. Signaling adapter proteins for c-Met, such as Grb2 and p85, exhibited reduced association with c-Met in cells that ectopically expressed CD82. These results indicate that the CD82-c-Met complex inhibits HGF-induced cancer cell migration by the inactivation of small GTP-binding proteins of the Rho family via c-Met adapter proteins. Copyright (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17621632     DOI: 10.1002/ijc.22887

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  24 in total

Review 1.  Tetraspanins and tumor progression.

Authors:  Mekel M Richardson; Lisa K Jennings; Xin A Zhang
Journal:  Clin Exp Metastasis       Date:  2010-12-24       Impact factor: 5.150

Review 2.  Targeting MET in cancer: rationale and progress.

Authors:  Ermanno Gherardi; Walter Birchmeier; Carmen Birchmeier; George Vande Woude
Journal:  Nat Rev Cancer       Date:  2012-01-24       Impact factor: 60.716

Review 3.  Tetraspanins: push and pull in suppressing and promoting metastasis.

Authors:  Margot Zöller
Journal:  Nat Rev Cancer       Date:  2008-12-11       Impact factor: 60.716

Review 4.  Tetraspanins in cell migration.

Authors:  Xupin Jiang; Jiaping Zhang; Yuesheng Huang
Journal:  Cell Adh Migr       Date:  2015-06-19       Impact factor: 3.405

Review 5.  Dissecting the diverse functions of the metastasis suppressor CD82/KAI1.

Authors:  Yien Che Tsai; Allan M Weissman
Journal:  FEBS Lett       Date:  2011-08-27       Impact factor: 4.124

6.  The tetraspanin CD151 is required for Met-dependent signaling and tumor cell growth.

Authors:  Mélanie Franco; Claudia Muratori; Simona Corso; Enrico Tenaglia; Andrea Bertotti; Lorena Capparuccia; Livio Trusolino; Paolo M Comoglio; Luca Tamagnone
Journal:  J Biol Chem       Date:  2010-10-11       Impact factor: 5.157

7.  Molecular cloning, expression pattern, and phylogenetic analysis of a tetraspanin CD82-like molecule in lamprey Lampetra japonica.

Authors:  Xiaoping Zhang; Xueying Song; Peng Su; Meng Gou; Hao Wang; Xin Liu; Qingwei Li
Journal:  Dev Genes Evol       Date:  2016-03-02       Impact factor: 0.900

Review 8.  The role of metastasis suppressor genes in metastatic dormancy.

Authors:  Christine E Horak; Jong Heun Lee; Jean-Claude Marshall; S Martin Shreeve; Patricia S Steeg
Journal:  APMIS       Date:  2008 Jul-Aug       Impact factor: 3.205

Review 9.  Tetraspanins as regulators of the tumour microenvironment: implications for metastasis and therapeutic strategies.

Authors:  S Detchokul; E D Williams; M W Parker; A G Frauman
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

10.  The tetraspanin KAI1/CD82 is expressed by late-lineage oligodendrocyte precursors and may function to restrict precursor migration and promote oligodendrocyte differentiation and myelination.

Authors:  Angeliki Mela; James E Goldman
Journal:  J Neurosci       Date:  2009-09-09       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.